Business Context and Reporting Period
This Form 8-K is a current report filed by Leap Therapeutics, Inc. (not Cypherpunk Technologies Inc.) on November 14, 2017. The filing discloses the entry into a material definitive agreement regarding a private placement of equity securities. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $18.0 million.
- Net Proceeds: Approximately $17.3 million (after deducting placement agent fees and estimated expenses of $0.7 million).
- Securities Issued: 2,958,094 shares of unregistered common stock.
- Price Per Share: $6.085.
- Warrants: Each share issued with a warrant to purchase one share at an exercise price of $6.085, expiring seven years after closing.
- Placement Agent Fees: 2.2% of aggregate gross proceeds plus reimbursement of certain expenses.
- Use of Proceeds: General corporate purposes.
Note: This filing does not provide revenue, profit, cash flow, margins, or debt figures for the company's operations.
Material Changes and Agreements
The primary material change is the execution of purchase agreements with institutional accredited investors and strategic partners, including HealthCare Ventures IX, L.P. and Eli Lilly and Company. Key terms include:
- Anti-Dilution Protection: Warrants include full ratchet anti-dilution provisions, subject to stockholder approval.
- Voting Agreement: The company entered into a voting agreement with HealthCare Ventures entities (holding a majority of voting shares) to vote in favor of the anti-dilution provisions at a special stockholder meeting.
- Registration Obligation: The company must file a registration statement for resale of shares and warrant shares within 30 days of closing and use best efforts to have it declared effective within 60 to 90 days.
Outlook, Risks, and Contingencies
- Stockholder Approval Contingency: The full ratchet anti-dilution protection is contingent upon stockholder approval. If not approved, these provisions will be of no force or effect.
- Regulatory Risk: The sale of shares and warrants relies on Section 4(a)(2) of the Securities Act of 1933 and has not been registered. Resale is restricted until the registration statement is effective.
- Future Capital: If all warrants are exercised, the company expects to receive an additional approximately $18.0 million in cash.
Investor Verification Checklist
- Verify the outcome of the special stockholder meeting regarding the full ratchet anti-dilution provisions.
- Confirm the effective date of the registration statement for the resale of shares and warrants.
- Review the full text of the Purchase Agreement (Exhibit 10.1) and Warrant (Exhibit 4.1) for specific covenants and limitations.
- Monitor the company's cash burn rate and runway given the "general corporate purposes" designation for the $17.3 million net proceeds.